NPPA fixes retail price of 19 formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 19 formulations, including those used to prevent heart attack and stroke and to treat high blood pressure, type 2 diabetes, heartburn, acid reflux and gastro-oesophageal reflux disease.
These include Windlas Biotech, Torrent Pharmaceuticals' Atorvastatin & Clopidogrel Capsule, used to prevent heart attack and stroke in the future. It lowers the raised level of cholesterol and fats (triglycerides) in our body.
Further, the list contains Pure and Cure Healthcare, Alembic Pharmaceuticals' Diclofenac Tablet, Windlas Biotech and Panacea Biotec Pharma's antidiabetic fixed dose combination drug Gliclazide plus Metformin Hydrochloride (Sustained release) Tablet, Micro Lab's Paracetamol plus Thiocolchicoside Tablet, Aristo Pharmaceutical's Pantaprozole Dualrelease Gastroresistant tablet (Aristo Pantop 80).
This price fixation is followed by the decisions made by the National Pharmaceutical Pricing Authority at its 87th Authority meeting dated 25.05.2021, where the Authority discussed new drug application price fixation under para 5 and para 15 of DPCO 2013.
This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Paracetamol + Phenylephrine + Caffeine+ Diphenhydramine Tablet | Each film coated tablet contains: Paracetamol IP 500 mg + Phenylephrine Hydrochloride IP 5 mg + Caffeine (anhydrous) 30 mg + Diphenhydramine Hydrochloride IP 25 mg | 1 Tablet | M/s Mediforce Healthcare Pvt. Ltd./ M/s Mankind Prime Labs Pvt. Ltd. | 3.21 |
2. | Gliclazide ER + Metformin ER Tablet | Each uncoated bilayered tablet contains: Gliclazide IP (as extended release form) 60mg Metformin Hydrochloride IP (As extended release form) 1000mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Eris Lifesciences Limited | 8.54 |
3. | Chlorthalidone + Telmisartan + Amlodipine Tablet | Each film coated tablet contains: Chlorthalidone IP 6.25mg | 1 Tablet | M/s Swiss Garnier Genexiaa Sciences / M/s | 8.92 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Telmisartan IP 40mg Amlodipine Besilate IP eq. to Amlodipine 5mg | USV Pvt. Ltd. | ||||
4. | Telmisartan + Cilnidipine Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg Cilnidipine IP 10mg | 1 Tablet | M/sWindlas Biotech Pvt. Ltd. / M/s USV Pvt. Ltd. | 9.66 |
5. | Gliclazide + Metformin Hydrochloride (Sustained release) Tablet | Each uncoated bilayered sustained release tablet contains: Gliclazide IP 60 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Windlas Biotech Pvt. Ltd. / Panacea Biotec Pharma Ltd | 8.54 |
6. | Atorvastatin & Clopidogrel Capsule | Each hard Gelatin Capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As two Film Coated Tablets Each containing Atorvastatin 10mg) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets Each containing 37.5 mg Clopidogrel) | 1 Capsule | M/s Windlas Biotech Limited / M/s Torrent Pharmaceuticals Limited | 16.70 |
7. | Telmisartan, Cilnidipine & Metoprolol (ER) Tablets | Each film coated bilayered tablet contains: Telmisartan IP 40mg Cilnidipine IP 10mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Alkem Laboratories Limited | 10.68 |
8. | Telmisartan, Cilnidipine & Metoprolol (ER) Tablets | Each film coated bilayered tablet contains: Telmisartan IP 40mg Cilnidipine IP 10mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Alkem Laboratories Limited | 12.95 |
9. | Metformin + Glimepiride Tablet | Each Uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (as | 1 Tablet | M/s Associated Biotech / M/s Dales Laboratories | 7.59 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Prolonged-Release) Glimepiride IP 2mg | |||||
10. | Atorvastatin & Clopidogrel Capsule | Each hard Gelatin Capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As Film Coated Tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) Each containing 37.5 mg Clopidogrel | 1 Capsule | M/s Windlas Biotech Limited / M/s Torrent Pharmaceuticals Limited | 12.55 |
11. | Diclofenac Tablet | Each film coated prolonged release tablet contains: Diclofenac Sodium IP 100mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Alembic Pharmaceuticals Ltd. | 6.68 |
12. | Metformin + Glimepiride Tablet | Each Uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (as Prolonged-Release) Glimepiride IP 1mg | 1 Tablet | M/s Associated Biotech / M/s Dales Laboratories | 6.25 |
13. | Telmisartan + Amlodipine + Hydrochlorothiazide Tablet | Each film coated tablet contains: Telmisartan IP 40 mg + Amlodipine Besilate IP eq. to Amlodipine 5mg + Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticlas Ltd. | 9.79 |
14. | Paracetamol + Thiocolchicoside Tablet | Each uncoated tablet contains: Paracetamol IP 500 mg Thiocolchicoside IP 4 mg | 1 Tablet | M/s Micro Labs Limited | 16.94 |
15. | Pantaprozole Dual- release Gastro- resistant tablet (Aristo Pantop 80) | Each Dual-release Gastro-resistant tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 80 mg | 1 Tablet | M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.74 |
16. | Calcium, Vitamin D3, Mecobalamin, L-Methylfolate Calcium & Pyridoxal-5- Phosphate Tablet | Each film coated tablet contains: Calcium Carbonate IP 1250mg eq. to Elemental Calcium 500mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. | 15.55 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Vitamin D3 IP 2000IU Mecobalamin IP (Methylcobalamin) 1500mcg L-Methylfolate Calcium 1mg Pyridoxal-5-Phosphate 20mg | |||||
17. | Diclofenac Transdermal Patch | Each 37.5 Sq cm Transdermal Patch contains: Diclofenac Diethylamine IP 100mg | 1 Patch | M/s Azista Industries Pvt. Ltd. / M/s Hetero Healthcare Ltd. | 31.25 |
18. | Diclofenac Diethylamine + Methyl Salicylate + Menthol topical Spray | Composition: Diclofenac Diethylamine IP 2.32% w/w (Eq. to Diclofenac Sodium 2% w/w) Methyl Salicylate IP 10% w/w Menthol IP 5% w/w | 1 Gram | M/s Pontika Aerotech Limited / M/s Intas Pharmaceuticals Limited | 2.93 |
19. | Paracetamol Infusion | Each 100ml contains: Paracetamol 1.0% w/v (10mg/ml) | 1 ML | M/s Axa Parenterals Limited / M/s Aristo Pharmaceuticals Pvt. Limited | 3.05 |
The notification further added;
(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
To view the official notice, click the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.